Suayip Yalcın
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 103
- Colorectal Cancer Treatments and Studies 26
- Pancreatic and Hepatic Oncology Research 16
- Lung Cancer Research Studies 14
- Cancer Immunotherapy and Biomarkers 13
-
- Gastric Cancer Management and Outcomes 28
- Co-authors
- Ece Esin (11 shared papers)Deniz Can Guven (45 shared papers)Taha Koray Şahin (27 shared papers)Sercan Aksoy (27 shared papers)Saadettin Kılıçkap (33 shared papers)Ömer Dızdar (41 shared papers)Cem Şimşek (2 shared papers)Enes Erul (6 shared papers)
- Journals
- Annals of Oncology (10 papers)Medical Oncology (8 papers)OncoTargets and Therapy (7 papers)Journal of Clinical Medicine (6 papers)Future Oncology (5 papers)
- Partner nations
- TürkiyeUnited StatesItaly
In The Last Decade
Suayip Yalcın
209 papers receiving 5.7k citations
Suayip Yalcın's Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 2.3k
- Gastroenterology 394
- Pulmonary and Respiratory Medicine 1.7k
- Hepatology 374
- Cancer Research 472
Countries citing papers authored by Suayip Yalcın
This map shows the geographic impact of Suayip Yalcın's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suayip Yalcın with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suayip Yalcın more than expected).
Fields of papers citing papers by Suayip Yalcın
This network shows the impact of papers produced by Suayip Yalcın. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suayip Yalcın. The network helps show where Suayip Yalcın may publish in the future.
Co-authors
The 25 scholars most cited alongside Suayip Yalcın, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 226 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1056 |
| 2 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 699 |
| 3 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 435 |
| 4 | Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2018 | 385 |
| 5 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 313 |
| 6 | 2022 | 166 | |
| 7 | 2019 | 112 | |
| 8 | 2017 | 111 | |
| 9 | 2019 | 100 | |
| 10 | 2015 | 94 | |
| 11 | 2015 | 67 | |
| 12 | 2014 | 65 | |
| 13 | 2024 | 62 | |
| 14 | 2021 | 59 | |
| 15 | 2013 | 58 | |
| 16 | 2014 | 54 | |
| 17 | 2023 | 54 | |
| 18 | 2015 | 50 | |
| 19 | 2021 | 50 | |
| 20 | 2019 | 49 |
About Suayip Yalcın
Suayip Yalcın is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Epidemiology, having authored 226 papers that have together received 5.8k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (28 papers), Colorectal Cancer Treatments and Studies (26 papers), Neuroendocrine Tumor Research Advances (23 papers), Cancer Genomics and Diagnostics (16 papers), Pancreatic and Hepatic Oncology Research (16 papers), Lung Cancer Research Studies (14 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Neuroblastoma Research and Treatments (13 papers). The work is most often cited by research in Oncology (2.3k citations), Gastroenterology (394 citations), Pulmonary and Respiratory Medicine (1.7k citations), Hepatology (374 citations) and Cancer Research (472 citations). Suayip Yalcın has collaborated with scholars based in Türkiye, United States and Italy. Frequent co-authors include Ece Esin, Deniz Can Guven, Taha Koray Şahin, Sercan Aksoy, Saadettin Kılıçkap, Ömer Dızdar, Cem Şimşek, Enes Erul, Şahin Laçin and Çağatay Arslan. Their work appears in journals such as Annals of Oncology, Medical Oncology, OncoTargets and Therapy, Journal of Clinical Medicine and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.